Consequently, the inhibition of glutaminolysis and mTOR was proposed as a potential strategy against Notch1-driven and, even, against anti-Notch1 therapy resistant ALL (141, 142). This evidence concerns the gene MTOR and acute lymphoblastic leukemia.